severe clinical reactions (influenza-like); there had been 19 moderate reactions (lesser degrees of constitutional illness), and the remaining 141 reactions had been graded mild, very mild, or nil. Only 2 volunteers were shown to have antibodies to M in the pre-trial serum samples, and 11 developed anti-M rises after virus inoculation. Nine of the 11 had had severe reactions, and 2 had had moderate reactions. There was, therefore, a clear correlation between severity of clinical illness and anti-M antibody formation. In general, anti-M increases coincided with increases to the hemagglutinins and nucleoprotein, and with virus shedding. However, no anti-M antibody could be demonstrated in paired sera of 18 additional volunteers of whom 12 had developed severe reactions after the inoculation of virulent HON1 and HlNl influenza A viruses and of whom 12 had shown laboratory evidence of infection.
Antibodies have long been known to occur in human sera to three major structural antigens of the influenza virus, the hemagglutinin (HA), neuraminidase (NA), and ribonucleoprotein (NP). More recently, a fourth major structural antigen, the matrix protein (M), has been described (14) ; this has type specificity and is now also known to stimulate antibody formation in human influenza virus infections (11) . Anti-HA antibodies are commonly measured by hemagglutination-inhibition (HI) (7) , anti-NA is measured by enzyme inhibition (1) , and anti-NP is measured by complement fixation, using socalled soluble antigen (8, 15) . Mostow et al. (11) have shown that the relatively simple technique of single radial diffusion (SRD) (15, 16) can be employed for the assay of all these antibodies and of anti-M. In addition, they described an association between anti-M formation in people naturally infected with A/Hong Kong/68 (H3N2) virus and clinical illness. The study has now been extended to volunteers of the MRC Common Cold Unit, Salisbury, England, who had been inoculated in controlled trials with influenza A viruses (H3N2, HlNl, and HON1) of varying degrees of virulence. Anti-M and anti-NP antibodies were assayed by SRD in paired sera and were considered in relation to other (15) . Differences of 35% or more in the zone areas produced by pre-and post-trial sera were considered significant, with respect to antibody rises, to both the M and NP proteins (11) .
RESULTS
Trial results. The clinical and laboratory data of the trials used in the study are summarized in Table 1 11 , and WRL 100, and attenuated strains like ts-1 (E), MRC 7 , and WRL 95, all induced significant numbers of increases in anti-NP in infected volunteers (Table 1 ). The total number ofincreases was 43. Zone areas produced by the sera ranged from O to 25 mm2, and increases were proportionately greatest in those who lacked antibody in their first sera.
Anti-M protein antibodies. Only 2 of the 180 pre-trial sera produced zones that were identified with anti-M antibody. It seemed therefore that this antibody was seldom formed in nature or, alternatively, that it persisted for only a short time. Eleven rises were seen in sera collected after the trials, and none of these volunteers had antibody initially. Zone annulus areas produced by the positive sera ranged from 6.5 to 12.8 mm2 (Table 2 ). All subjects showing anti-M rises had also had significant HI rises, seven had had anti-NP rises, and all had excreted virus on days 3 and/or 4 after inoculation, the only days on which nasal washings had been routinely collected. All sera with detectable anti-M antibody also contained antibody to NP. Among the 11 individuals who developed anti-M, 9 clinical reactions were graded "severe" (influenza-like), and 2 were "moderate" (coryza and constitutional symptoms). Clinical scores ranged from 27 to 90, with an average of 57.8, compared with 0 to 90 and an average of 18.4 for the 123 people in the combined trials who had laboratory evidence of infection (Table 1) (Table 3) , and these contained M proteins that were not necessarily closer to each other than they were to that of virus 'N' (H av 2 Neql). In addition, they contained surface antigens whose survival might have led to interaction with antibodies found in human sera. However, no antigenic differences have been detected between the M antigens of human H3N2, HON1, or H2N2 viruses, or of avian influenza A viruses (14; G. C. Schild, unpublished data), and thus it is unlikely that the failure to detect anti-M in those infected with HON1 or HlNl was due to heterogeneity in the specificity of antibody response to different subtypes of influenza A virus.
In humans, anti-M may mediate some minor degree of cross-protection between different influenza virus subtypes or, alternatively, may be associated with immunopathological aspects of the disease. However further studies are required to establish the possible role of humoral or cellular aspects of immunity to M in these phenomena. A practical application of anti-M antibody assays may be as a laboratory parameter of the severity of human infections with H3N2 viruses.
